Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
December 26, 2023 07:13 ET
|
Rayzebio, Inc.
Transaction Brings RayzeBio’s Differentiated Actinium-Based Radiopharmaceutical Platform, Including Rich Pipeline of Multiple Drug Development Programs to Bristol Myers Squibb’s Leading Oncology...
RayzeBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 13, 2023 16:01 ET
|
Rayzebio, Inc.
SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- RayzeBio, Inc. (Nasdaq: RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today...
RayzeBio to Participate in Upcoming Investor Conferences in November 2023
November 06, 2023 16:05 ET
|
Rayzebio, Inc.
SAN DIEGO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- RayzeBio, Inc. (Nasdaq: RYZB), a biopharmaceutical company developing an innovative radiopharmaceutical pipeline to treat different cancers, today...
RayzeBio Appoints Industry Leader Tim Van Hauwermeiren to Its Board of Directors
November 01, 2023 06:00 ET
|
Rayzebio, Inc.
SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- RayzeBio, Inc. (Nasdaq: RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today...
FDA selects RayzeBio to Participate in the Inaugural CDRP Program to Expedite Commercial Manufacturing Readiness for RYZ101 in GEP-NETs
October 24, 2023 08:00 ET
|
Rayzebio, Inc.
SAN DIEGO, Oct. 24, 2023 (GLOBE NEWSWIRE) -- RayzeBio, Inc. (Nasdaq: RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today...
RayzeBio to Present at European Society for Medical Oncology (ESMO) Congress
October 18, 2023 07:00 ET
|
Rayzebio, Inc.
SAN DIEGO, Oct. 18, 2023 (GLOBE NEWSWIRE) -- RayzeBio, Inc. (Nasdaq: RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today...